Spectral Med reported EPS of C$0.02 for the quarter ended September 30, beating the C$0.01 loss analysts expected. Investors are also watching the company’s FDA review and recent financing.
Spectral Med Inc. (TSX: EDT) reported earnings before market open on November 6, 2026. For the fiscal quarter ended September 30, EPS was C$0.02, compared with one analyst’s estimate of -C$0.01. That works out to a reported surprise of 300.0%. Since the estimate came from just one analyst, it offers a limited comparison, not a broad consensus. The revenue estimate was C$604,000, but no actual revenue figure was provided. Follow EDT.TO on the EDT stock page.
Recent earnings trend
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$284.75M
52W high
$1.52
52W low
$0.86
1W change
-5.83%
Beta
0.19
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 224.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+224.7% Upside
Current Price
C$0.97
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
68.3%
Annualized
90-Day Vol
48.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.91 | C$0.72 – C$1.16 |
| 60 trading days | C$0.86 | C$0.62 – C$1.20 |
| 90 trading days | C$0.81 | C$0.54 – C$1.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-29 | — | -0.0100 | — |
| 2026-09-30 | 2026-11-06 | 0.0200 | -0.0100 | +300.0% |
| 2026-06-30 | 2026-08-07 | 0.0011 | -0.0100 | +111.0% |
| 2026-03-31 | 2026-05-08 | -0.0100 | -0.0100 | +0.0% |
| 2025-12-31 | 2026-03-26 | -0.0100 | -0.0200 | +50.0% |
| 2025-09-30 | 2025-11-07 | -0.1100 | -0.0100 | -1000.0% |
Investor takeaway: EDT beat the single-analyst EPS estimate and has beaten estimates in three of its last four reported quarters. Still, the result doesn’t resolve the bigger questions: the company remains loss-making on a trailing basis, and its regulatory progress and ability to fund operations matter. Spectral says it is responding to FDA requests related to its PMA review and that recent financing is intended to fund operations through an anticipated decision. These are company updates, not guarantees of approval or timing.
C$0.02 EPS versus -C$0.01 estimated
The reported 300.0% surprise reflects the difference between actual EPS and one analyst’s negative estimate. EPS was -C$0.11 in the year-ago quarter. On its own, that improvement doesn’t show that the company has reached sustained profitability.
Bull case
EPS improved from -C$0.11 a year earlier to C$0.02, based on the reported figures. Spectral has also beaten estimates in three of its last four comparable quarters. The company says its recent financing should fund operations through the anticipated FDA PMA decision. In a September update, it said the FDA had not requested another clinical trial and that it did not expect a material change to the overall regulatory timeline. Analyst price targets are well above the latest close, but coverage is limited and targets depend on assumptions.
Bear case
The estimate came from one analyst, so it’s a narrow benchmark. The supplied figures also don’t include actual quarterly revenue or margins. Spectral’s trailing EPS is -C$0.12, and its reported profit margin is 0.00%. After receiving a deficiency letter, the company said it was addressing FDA requests for clarification, additional data analysis and testing. The review remains uncertain. Spectral’s recent C$14 million convertible-note placement also raises financing and potential dilution concerns. Shares closed at C$0.97, below their 50-day and 200-day moving averages.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
